Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)
|
May 19, 2023
ADAMTS13 Activity: Screening Test Protocol
Gary W Moore, Margaret Griffiths, Nikolaus B Binder
Methods in Molecular Biology (Clifton, N.J.)
|
May 19, 2023
ADAMTS13 Antibody and Inhibitor Assays
Gary W Moore, Helga Vetr, Nikolaus B Binder
Analytical Biochemistry
|
May 19, 2020
Feasibility of an automated coagulation factor XIIIa test using its isopeptidase activity
Martina Leitner, Christian Büchold, Ralf Pasternack, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
May 19, 2023
ADAMTS13 Activity Measurement by ELISA and Fluorescence Resonance Energy Transfer Assay
Gary W Moore, Marcos Llusa, Margaret Griffiths, et al.
International Journal of Molecular Sciences
|
January 27, 2021
Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity
Martina Leitner, Christian Büchold, Ralf Pasternack, et al.
Journal of Molecular Neuroscience : MN
|
September 24, 2009
Interleukin-1 mediates long-term hippocampal dentate granule cell loss following postnatal viral infection
Anna G Orr, Anup Sharma, Nikolaus B Binder, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 30, 2021
Clinical use of thrombin generation assays
Nikolaus B Binder, François Depasse, Julia Mueller, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 15, 2021
Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine
François Depasse, Nikolaus B Binder, Julia Mueller, et al.
Journal of Thrombosis and Haemostasis : JTH
|
July 11, 2024
Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL
Bert Verbruggen, Nikolaus B Binder, Petra J C van Velp, et al.
Arthritis and Rheumatism
|
January 3, 2013
Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis
Nikolaus B Binder, Antonia Puchner, Birgit Niederreiter, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Methods in Molecular Biology (Clifton, N.J.)
|
May 19, 2023
ADAMTS13 Activity: Screening Test Protocol
Gary W Moore, Margaret Griffiths, Nikolaus B Binder
Methods in Molecular Biology (Clifton, N.J.)
|
May 19, 2023
ADAMTS13 Antibody and Inhibitor Assays
Gary W Moore, Helga Vetr, Nikolaus B Binder
Analytical Biochemistry
|
May 19, 2020
Feasibility of an automated coagulation factor XIIIa test using its isopeptidase activity
Martina Leitner, Christian Büchold, Ralf Pasternack, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
May 19, 2023
ADAMTS13 Activity Measurement by ELISA and Fluorescence Resonance Energy Transfer Assay
Gary W Moore, Marcos Llusa, Margaret Griffiths, et al.
International Journal of Molecular Sciences
|
January 27, 2021
Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity
Martina Leitner, Christian Büchold, Ralf Pasternack, et al.
Journal of Molecular Neuroscience : MN
|
September 24, 2009
Interleukin-1 mediates long-term hippocampal dentate granule cell loss following postnatal viral infection
Anna G Orr, Anup Sharma, Nikolaus B Binder, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 30, 2021
Clinical use of thrombin generation assays
Nikolaus B Binder, François Depasse, Julia Mueller, et al.
Journal of Thrombosis and Haemostasis : JTH
|
September 15, 2021
Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine
François Depasse, Nikolaus B Binder, Julia Mueller, et al.
Journal of Thrombosis and Haemostasis : JTH
|
July 11, 2024
Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL
Bert Verbruggen, Nikolaus B Binder, Petra J C van Velp, et al.
Arthritis and Rheumatism
|
January 3, 2013
Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis
Nikolaus B Binder, Antonia Puchner, Birgit Niederreiter, et al.
Page
of 3